Zhong Guo Jing Ji Wang·2025-12-01 07:12Core Viewpoint - The Shanghai Stock Exchange has decided to terminate the review of Zhejiang Huakang Pharmaceutical Co., Ltd.'s asset acquisition and related transactions, leading the company to withdraw its application for the issuance of shares and cash payment for the acquisition of Henan Yuxin Sugar Alcohol Co., Ltd. [1][3][4] Group 1: Termination of Transaction - Huakang Pharmaceutical announced the termination of its plan to acquire 100% of Yuxin Sugar Alcohol through a combination of share issuance and cash payment, following discussions with relevant parties [3][4] - The decision to terminate the transaction was made after careful consideration by the company's board, citing significant changes in the market environment since the initial planning of the transaction [4] Group 2: Financial Performance - In 2024, Huakang Pharmaceutical reported a revenue of 2.81 billion, a year-on-year increase of 0.93%, while the net profit attributable to shareholders decreased by 27.72% to 268 million [6][8] - For the first three quarters of 2025, the company achieved a revenue of 2.96 billion, reflecting a year-on-year growth of 40.52%, but the net profit attributable to shareholders decreased by 9.91% to 168 million [6][9] Group 3: Transaction Details - The proposed transaction involved a total price of 1.098 billion, with 732 million to be paid in shares and 366 million in cash, and was assessed to have an estimated value of 1.101 billion for the 100% equity of Yuxin Sugar Alcohol [5][6] - The evaluation indicated a significant increase in value, with an appreciation of 55.6 million, resulting in a growth rate of 102.01% compared to the company's net assets [6]